Ilodecakin

Drug Profile

Ilodecakin

Alternative Names: Human recombinant interleukin 10; Interleukin-10; Prevascar; rhIL-10; rIL-10; SCH-52000

Latest Information Update: 11 Jun 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Schering-Plough
  • Developer Renovo
  • Class Anti-inflammatories; Antineoplastics; Interleukins
  • Mechanism of Action Interleukin-10 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute lung injury; Autoimmune disorders; Cancer; Crohn's disease; Graft-versus-host disease; Growth disorders; Hepatic fibrosis; Hepatitis C; Herpes simplex virus infections; HIV infections; Multiple sclerosis; Myocarditis; Pancreatitis; Psoriasis; Reperfusion injury; Rheumatoid arthritis; Scars; Sepsis; Transplant rejection; Type 1 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 06 Jun 2013 ARMO Biosciences completes acquisition of all rights to ilodecakin previously held by Renovo
  • 13 Dec 2012 Targenics agrees to purchase all rights to ilodecakin held by Renovo
  • 16 Apr 2012 Discontinued - Phase-II for Scars (prevention) in United Kingdom (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top